Abstract

The challenge for today's pharmaceutical industry lies in the discovery and development of new, pharmacologically active molecules. Metabolites produced by microorganisms, and fungi in particular, are a resource for which the therapeutic potential has been recognized, but one that remains largely unexplored and unexploited. Approximately 20% of all known fungal species are obligate symbionts in lichens; this major group of fungi has been long neglected by mycologists, and overlooked by industry.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call